CG Oncology Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

CGON$72.64-2.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Revenues
Research and collaboration revenue	$43	$9	$683	$203
Operating expenses
Research and development	19,622	11,735	55,302	29,412
General and administrative	8,716	2,317	21,998	6,885
Total operating expenses	28,338	14,052	77,300	36,297
Loss from operations	(28,295)	(14,043)	(76,617)	(36,094)
Other income (expense), net:
Interest income, net	7,892	2,283	20,379	4,100
Other (expense) income, net	(2)	(8)	(3)	(58)
Total other income (expense), net	7,890	2,275	20,376	4,042
Net loss and comprehensive loss	$(20,405)	$(11,768)	$(56,241)	$(32,052)
Deemed dividend on redeemable convertible preferred stock issuances	—	(410)	—	(410)
Cumulative redeemable convertible preferred stock dividends	—	(5,336)	—	(12,846)
Net loss attributable to common stockholders	$(20,405)	$(17,514)	$(56,241)	$(45,308)
Net loss per share, basic and diluted	$(0.30)	$(4.00)	$(0.93)	$(11.18)
Weighted average shares of common stock outstanding, basic and diluted	67,143,744	4,383,131	60,311,003	4,053,341

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.